Findings seen in patients with posterior circulation stroke and with no planned thrombectomy who received alteplase 4.5 to 24 hours after stroke onset.

The University of Wisconsin Hospital and Clinics (UWHC) determined that alteplase should be used to lyse catheter clots, even though the drug is very costly at doses previously studied.

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

Download a PDF of the Research Summary. A total of 234 patients were enrolled; 117 were assigned to the alteplase group and 117 to the standard treatment group. The median score on the National ...

In 1996, a drug called alteplase was approved by the Food and Drug Administration (FDA) to treat AIS, nearly a decade after it was approved to treat heart attacks. It works by attaching to a ...

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to those given alteplase Tenecteplase is easier to administer, giving doctors ...

T he clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary late ...

The researchers found that the percentage of patients with functional independence at 90 days was higher in the alteplase group versus the standard treatment group (89.6% versus 72.6%; adjusted ...

Intravenous alteplase (recombinant tissue plasminogen activator) is restricted for use within 3 h from stroke onset by marketing authorizations. Some patients are treated beyond this approved time ...

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to those given alteplase Tenecteplase is easier to administer, giving ...

Boehringer Ingelheim (BI) is celebrating after an independent evaluation in the UK has reconfirmed that the benefits of its clot-busting drug alteplase outweigh the risks for acute ischaemic ...